Glucocorticoid-induced Osteoporosis
📧 Sign up to get email alerts when something new happens for Glucocorticoid-induced Osteoporosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study [Phase 4]
A Phase 4 pilot study evaluating discontinuation and switching strategies for denosumab in glucocorticoid-induced osteoporosis.
-
FDA approval · 2026-04-15FDA Approved: ALENDRONATE SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ALENDRONATE SODIUM submitted by Aurobindo Pharma Limited.
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease [Phase 2]
Phase 2 clinical trial evaluating methods to identify individuals at risk of glucocorticoid-induced osteoporosis. Sponsored by Odense Univer…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China [Phase 4]
A Phase 4 clinical trial evaluating the efficacy and safety of Prolia (denosumab) for glucocorticoid-induced osteoporosis in Mainland China.…
-
FDA approval · 2026-02-03FDA Approved: ALENDRONATE SODIUM — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' supplemental application for alendronate sodium, updating the approved product under the ANDA.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-12-12FDA Approved: TERIPARATIDE — Original Application (Amphastar Pharmaceuticals, Inc.)
FDA approved Amphastar Pharmaceuticals' original application for a generic teriparatide product.
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: The Role of Vitamin K2 in Preventing Glucocorticoid-Induced Bone Loss in Children With Nephrotic Syndrome [NA]
A clinical trial sponsored by Ain Shams University is evaluating whether Vitamin K2 can prevent glucocorticoid-induced bone loss in children…
-
CLINICAL_TRIALS research · 2024-11-22Clinical Trial Update: Romosozumab Versus Denosumab in GIOP: a 2-year Extension Study [Phase 4]
Phase 4 extension trial comparing romosozumab versus denosumab in glucocorticoid-induced osteoporosis to assess two-year outcomes; recruitme…
-
FDA approval · 2024-11-07FDA Approved: TERIPARATIDE — Supplemental Application (Apotex Corp.)
FDA approves Apotex Corp.'s supplemental application for a generic teriparatide product.
-
FDA approval · 2024-11-06FDA Approved: TERIPARATIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for Teriparatide (teriparatide), enabling marketing of a generic teriparatide product. This act…
-
FDA approval · 2024-09-27FDA Approved: ALENDRONATE SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ALENDRONATE SODIUM by Aurobindo Pharma Limited (generic).
-
CLINICAL_TRIALS trial_result · 2024-09-04Clinical Trial Update: Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users [Phase 4]
Phase 4 head-to-head trial comparing romosozumab to denosumab in long-term glucocorticoid users with osteoporosis has completed. No results …
-
CLINICAL_TRIALS trial_result · 2024-07-19Clinical Trial Update: Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis [Phase 3]
Phase 3 trial evaluating safety and efficacy of denosumab in pediatric patients with glucocorticoid-induced osteoporosis. Results were poste…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: A Study on the Prevention and Treatment of GIOP With Eldecalcitol [Phase 4]
Phase 4 clinical trial update evaluating eldecalcitol for prevention and treatment of glucocorticoid-induced osteoporosis, with study popula…
-
FDA approval · 2024-01-08FDA Approved: RISEDRONATE SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for risendronate sodium by Sun Pharmaceutical Industries, expanding or modifying its labeling un…
-
FDA approval · 2023-12-18FDA Approved: RISEDRONATE SODIUM — Supplemental Application (Sun Pharmaceutical Industires Inc.)
The FDA approved a supplemental application for Risedronate Sodium submitted by Sun Pharmaceutical Industries Inc.
-
FDA approval · 2023-11-16FDA Approved: TERIPARATIDE — Supplemental Application (Alvogen, Inc.)
The FDA approved a supplemental application for teriparatide submitted by Alvogen, Inc.
-
FDA approval · 2023-06-07FDA Approved: RISEDRONATE SODIUM — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for risendronate sodium from Macleods Pharmaceuticals Limited.
-
FDA approval · 2023-06-06FDA Approved: ALENDRONATE SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ALENDRONATE SODIUM from Aurobindo Pharma Limited, enabling the approved generic formulation to b…
-
FDA label_change · 2023-04-28FDA Approved: RISEDRONATE SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical Industries, Inc.'s supplemental application for risedronate sodium, resulting in updated labeling. This …
-
FDA approval · 2023-01-31FDA Approved: ALENDRONATE SODIUM — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
The FDA approved a supplemental application for alendronate sodium from Amneal Pharmaceuticals of New York LLC for use as a generic product …
-
CLINICAL_TRIALS trial_result · 2022-05-31Clinical Trial Update: Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis [Phase 2]
Phase 2 clinical trial update evaluating efficacy and safety of JMT103 for glucocorticoid-induced osteoporosis.
-
FDA approval · 2021-09-07FDA Approved: TERIPARATIDE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for teriparatide submitted by Prasco Laboratories. This action relates to a supplemental approva…
-
FDA approval · 2020-11-16FDA Approved: TERIPARATIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for teriparatide submitted by Prasco Laboratories, expanding or updating the drug's regulatory statu…
-
FDA approval · 2020-10-13FDA Approved: BINOSTO — Supplemental Application (Radius Health, Inc.)
The FDA approved a supplemental application for BINOSTO (alendronate sodium) from Radius Health, Inc., supporting a label expansion/updated …